Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Gauvreau GM, Hohlfeld JM, FitzGerald MJ, Boulet LP, et al. Eur Respir J 2023 Feb 23:2201193. doi: 10.1183/13993003.01193-2022.

Read + Share

Amedeo Smart

Independent Medical Education

Gauvreau GM, Hohlfeld JM, FitzGerald MJ, Boulet LP, et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Eur Respir J 2023 Feb 23:2201193. doi: 10.1183/13993003.01193-2022.
PMID: 36822634